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Abstract: For the past 100 years, oncologists have relentlessly pursued the destruction of tumor
cells by surgical, chemotherapeutic or radiation oncological means. Consistent with this focus,
treatment plans are typically based on key characteristics of the tumor itself such as disease site,
histology and staging based on local, regional and systemic dissemination. Precision medicine
is similarly built on the premise that detailed knowledge of molecular alterations of tumor cells
themselves enables better and more effective tumor cell destruction. Recently, host factors within
the tumor microenvironment including the vasculature and immune systems have been recognized
as modifiers of disease progression and are being targeted for therapeutic gain. In this review,
we argue that—to optimize the impact of old and new treatment options—we need to take account
of an epidemic that occurs independently of—but has major impact on—the development and
treatment of malignant diseases. This is the rapidly increasing number of patients with excess weight
and its’ attendant metabolic consequences, commonly described as metabolic syndrome. It is well
established that patients with altered metabolism manifesting as obesity, metabolic syndrome and
chronic inflammation have an increased incidence of cancer. Here, we focus on evidence that these
patients also respond differently to cancer therapy including radiation and provide a perspective how
exercise, diet or pharmacological agents may be harnessed to improve therapeutic responses in this
patient population.
Keywords: host metabolism; obesity; caloric restriction; dietary interventions; cancer
therapy; radiation
1. Introduction
The seminal work by Warburg and colleagues directed attention to the metabolic interface between
tumor cells and the host organism [1]. Much of the work accomplished since has focused on how tumor
cells marshal resources in their microenvironment to meet their metabolic demands. By contrast, less
is known about how metabolic states of the body beyond the tumor itself affect tumor progression and
therapy responses. Obesity and poor diets have been recognized as a profound contributor to the global
burden of disease contributing to more than four million deaths annually [2]. While the functional
contribution of obesity to high blood pressure, stroke, heart disease and type II diabetes is widely
recognized, its contribution to cancer outcomes, responses to therapy and toxicity is less appreciated.
In the following we will outline evidence in support of the notion that metabolic states and diseases
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associated with obesity impact not only cancer incidence, but also the response to treatment including
radiation- and chemo- therapy. A better understanding of these relationships is urgently needed to
address the consequences for cancer therapy on the dramatic increase in obesity in Western societies
and, increasingly, societies around the world. We will further outline therapeutic opportunities and
approaches to redress the unfavorable effects of obesity-associated metabolic diseases on tumor therapy.
2. Altered Metabolism Impacts Cancer Outcomes
Despite the major progress in tailored cancer therapy facilitated by precision medicine approaches,
overall life expectancy in the USA has decreased for three consecutive years, representing the longest
consecutive decline in American lifespan since the period between 1915 and 1918, which included
World War I and the Spanish Flu pandemic [3]. In part, this may be attributed to increased cancer
incidence in overweight and obese patients. Annually in the USA alone, 85,000 cancer cases are linked
to obesity and this number is projected to rise to 500,000 cases by 2030 [4]. The UK has similarly
experienced a marked increase in obesity-related cancer cases as documented in a landmark study of
5.2 million patients, indicating a positive linear relationship between BMI (body mass index kg/m2)
and cancer incidence [5].This increase in obesity-related cancers is mirrored by an estimated 20%
excess increase in overall cancer mortality [5] and has been noted for a broad range of malignancies
including breast, lung, colon, pancreatic, esophageal, genitourinary and gynecological cancers [6,7].
Postmenopausal women with high BMI have been shown to be at a 20%–40% higher risk of developing
hormone positive breast cancers [8], while obese premenopausal women are at a greater than 42% risk
of developing hormone negative or triple-negative breast cancer (TNBC) [9].
Conversely, underweight patients have a lower rate of cancer incidence compared to the general
population. A retrospective cohort study of women with a history of anorexia nervosa demonstrated a
comparable 50% decrease in the incidence of breast cancer, suggesting that caloric restriction (CR) in
humans may confer protection against invasive breast cancer [10]. Similarly, a Danish registry revealed
that patients with a diagnosis of anorexia nervosa manifested a lower overall cancer risk for a variety
of cancers [11].
Additional evidence suggests that the relationship between increased bodyweight and
cancer extends to patients who develop metabolic syndromes both during and following cancer
treatment [12,13]. In fact, weight gain frequently occurs following a cancer diagnosis. Breast cancer
patients gain ten to twenty pounds on average in the first year after diagnosis and this weight gain is
directly linked to worse cancer outcomes. The nurses’ health study of 5204 participants with invasive,
nonmetastatic breast cancer examined the impact of weight gain after time of diagnosis on clinical
outcomes. An increase in BMI during treatment was associated with elevated rates of breast cancer
death, distant recurrence and all-cause mortality [14]. A randomized multi-institutional phase III
clinical trial enrolling breast cancer patients (women’s intervention nutrition study), revealed that
reducing fat intake was associated with a significant increase in relapse-free survival than the control
group [15,16]. The cause for weight gain after a cancer diagnosis is poorly understood, but appears to
be multifactorial. In part, patients may reduce physical activity and increase food intake as a means to
cope with their diagnosis [17–19]. In addition, cancer therapy adversely affects the metabolic state of
the patient and contributes to weight gain. For example, chemotherapy is often administered with
a pretreatment dose of steroids. Despite the relatively low doses, incorporation of steroids into a
treatment regimen appears to be associated with weight gain [20,21]. Anti-estrogen therapies used
in breast cancer and androgen deprivation therapies used in prostate cancer have also been shown
to affect a patient’s metabolism, incite weight gain and even lead to the development of metabolic
syndrome [22–24]. This is an integral part of a vicious circle in which therapeutic intervention is
thwarted by creating and amplifying metabolic imbalances, which support cancer cell survival and
growth. (Figure 1) Collectively, these observations call for the development of novel strategies to break
the cycle and reset metabolic imbalances before and during cancer therapy.
Cancers 2020, 12, 2338 3 of 20Cancers 2020, 12, x  3 of 19 
 
Figure 1. Host and tumor metabolism: a vicious cycle. Obesity, metabolic syndrome and a chronic 
inflammatory state have led to an increase in the incidence of obesity-related malignancies and 
expansion of patients undergoing chemo-and radiotherapy. These cytotoxic treatments have been 
linked to weight gain and development of metabolic syndrome post-diagnosis leading to poor 
outcomes, earlier recurrences and potential development of subsequent obesity-related cancers. 
2.1. Altered Metabolism Is Associated with Decreased Efficacy of Radiation and Other Cancer Therapies 
In addition to developing cancer at higher frequency than patients with normal BMI, overweight 
and obese patients have worse outcomes after therapy. In part this may be due to the fact that obese 
patients may be undertreated due to difficulties surrounding treatment planning [25]. However, this 
association also holds true in patient populations receiving standard therapy. For example, prostate 
cancer patients with increased BMI and receiving dose-escalated intensity modulated radiation 
therapy (IMRT) are at increased risk of distant metastasis, prostate-specific mortality and overall 
mortality [26]. In a similar retrospective study in patients with breast cancer brain metastases 
receiving intracranial radiation, increased BMI is associated with decreased overall survival (OS) and 
reduced progression free survival (PFS) [27]. It has been hypothesized that a patients’ girth may be a 
factor in poor control, setup and reproducibility of radiation delivery to the prostate and other areas 
at risk. However, this seems unlikely as worse outcomes were also reported in high BMI prostate 
cancer patients treated with brachytherapy which allows precise delivery of radiation to the organ 
unencumbered by body mass [28]. Similarly, in breast cancer, it has been proposed that technical 
difficulties unique to obese patients cause insufficient radiation delivery to target tissues. However, 
based on the studies in prostate cancer it is possible that metabolic alterations associated with 
increased BMI contribute to radiation resistance of breast cancer cells in situ. It is tempting to 
speculate that the hyperinsulinemia and/or hyperglycemia prevalent in prediabetic or diabetic 
patients may contribute to radiation resistance of tumor cells in those patients. Furthermore, areas of 
high glycolytic rates are believed to confer protection from reactive oxygen species (ROS)-induced 
DNA damage by supplying large amounts of antioxidants [29,30]. However, studies in animal 
models found insufficient evidence to support a direct link between glucose uptake by cells and 
radiation resistance [31]. Thus, the molecular mechanisms and correlates of radioresistance of 
malignant cells and lesions in obese patients remain elusive. 
2.2. Altered Metabolism Is Associated with Increased Radiation Toxicity 
Across disease sites, it is clear that obesity and diabetes also increase the risk to incur adverse 
effects during and after radiation treatment. Breast cancer patients with a BMI ≥ 30 kg/m2 and 
undergoing radiation therapy have an increased risk of developing lymphedema and other 
treatment-related side effects (Analysis of the Health, Eating, Activity and Lifestyle Study). [32] In 
Figure 1. Host and tumor metabolism: a vicious cycle. Obesity, metabolic syndrome and a chronic
inflammatory state have led to an increase in the incidence of obesity-related malignancies and
expansion of patients undergoing chemo-and radiotherapy. These cytotoxic treatments have been
linked to weight gain and development of metabolic syndrome post-diagnosis leading to poor outcomes,
earlier recurrences and potential development of subsequent obesity-related cancers.
2.1. Altered Metabolism Is Associated with Decreased Efficacy of Radiation and Other Cancer Therapies
In addition to developing cancer at higher frequency than patients with normal BMI, overweight
and obese patients have worse outcomes after therapy. In part this may be due to the fact that obese
patients may be undertreated due to difficulties surrounding treatment planning [25]. However, this
association also holds true in patient populations receiving stand rd therapy. For example, prostate
cancer patients with increased BMI and receiving dose-escalated intensity modulated radiation therapy
(IMRT) are at increased risk of distant metastasis, prostate-specific mortality and overall mortality [26].
In a similar retrospective study in patients with breast cancer brain metastases receiving intracranial
radiation, increased BMI is associated with decreased overall survival (OS) and reduced progression
free survival (PFS) [27]. It has been hypothesized that a patients’ girth may be a factor in poor control,
setup and r producibility of adiation delivery to he pro tate and other areas at risk. However,
this seems unlikely as worse outcomes were also reported in high BMI prostate cancer patients treated
with brachytherapy which allows precise delivery of radiation to the organ unencumbered by body
mass [28]. Similarly, in breast cancer, it has been proposed that technical difficulties unique to obese
patients cause insufficient radiation delivery to target tissues. However, based on the studies in prostate
cancer it is possible that metabolic alterations associated with increased BMI contribute to radiation
resistance of breast cancer cells in situ. It is t mpting to speculate that th hyperinsulinemia and/or
hyperglycemia prevalent in prediabetic or diabetic patients may contribute to radiation resistance
of tumor cells in those patients. Furthermore, areas of high glycolytic rates are believed to confer
protection from reactive oxygen species (ROS)-induced DNA damage by supplying large amounts of
antioxidants [29,30]. However, studies in animal models found insufficient evidence to support a direct
link between glucose uptake by cells and radiation resistance [31]. Thus, the molecular mechanisms
and correlates of radioresistance of malignant cells and lesions in obese patients remain elus ve.
2.2. Altered Metabolism Is Associated with Increased Radiation Toxicity
Across disease sites, it is clear that obesity and diabetes also increase the risk to incur adverse effects
during and after radiation treatment. Breast cancer patients with a BMI ≥ 30 kg/m2 and undergoing
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radiation therapy have an increased risk of developing lymphedema and other treatment-related side
effects (Analysis of the Health, Eating, Activity and Lifestyle Study). [32] In addition, overweight and
obese men are more prone to developing late pelvic symptoms after radiotherapy for prostate cancer,
including higher rates of rectal bleeding and nocturia [33]. Similarly, in women with endometrial
cancer treated with radiation, mean BMI positively correlates with higher-grade radiation-related
gynecologic and cutaneous toxicities [34]. An analysis of pulmonary tumors less than 2.5 cm from the
chest wall treated with stereotactic body radiation therapy (SBRT) further found that BMI was the
strongest predictor of chest wall pain after treatment, with patients whose BMI was ≥29 having nearly
twice the risk of chronic chest wall pain than patients with lower BMI [35]. Additionally, patients with
poor glycemic control are noted to have increased cognitive and functional decline as noted by white
matter changes following whole brain radiotherapy for brain metastases [36].
3. Metabolic Alterations and Inflammation
Both cancer development and obesity-related comorbid conditions are closely linked to chronic
inflammation. Rudolf Virchow first suggested that cancer may develop at sites of chronic inflammation
based on his observation of leukocytic infiltrates in tumor tissues. A broad base of epidemiological
evidence collected since supports this concept and has demonstrated that tumor cells often co-opt
mediators of chronic inflammation to support malignant traits ranging from cell proliferation to
metastatic spread [37]. Adipose tissue has been recognized as a rich source for autocrine, paracrine
and endocrine proteins—collectively termed adipokines—that act in concert with proinflammatory
cytokines to contribute to organism-wide chronic inflammatory states. The systemic effects of chronic
inflammation in the fat tissue of obese individuals on tumor cell growth and development are poorly
understood. However, evidence is emerging that obesity-linked inflammation has extensive effects
on tumor growth, antitumor immune responses and, potentially, the efficacy of immunotherapeutic
approaches [38–40].
The immune environment of adipose tissues in lean and overweight or obese patients is markedly
different, both in cytokine expression patterns and in cell composition and phenotype. This is perhaps
most evident for innate immune cells of the myeloid lineage, i.e., monocytes and macrophages that
reside in fat tissue. Whereas in lean individuals these commonly display a predominant regulatory M2
phenotype, in obese individuals they are polarized toward the M1 phenotype characterized by the
production of proinflammatory cytokines including tumor necrosis factor (TNF)α, interleukin (IL)-6
and IL-1β, as well as monocyte chemoattractants including monocyte chemoattractant protein (MCP)-1
and macrophage inhibitory factor (MIF) [41,42]. Within the adipose tissue these macrophages may
then be biased towards the M1 phenotype by exposure to oxidative stress, hypoxia and recognition
of pattern/danger associated molecular signals (PAMPS/DAMPS) that activate Toll-like receptors
(TLRs) [43]. TLR stimulation triggers nuclear factor (NF)-κB-signaling and reinforces production
and secretion of proinflammatory cytokines [44–47]. The inflamed status of adipose tissues in
obese individuals exerts systemic effects and affects immune homeostasis at distant sites including
malignant tumors. For example, serum levels of several cytokines including IL-6 and TNFα are
elevated in obese individuals [48]. IL-6 activates signal transducer and activator of transcription
(STAT)3-signaling in immune and tumor cells and skews the differentiation state of myeloid cells
towards immunosuppressive phenotypes [49,50]. Importantly, reduced caloric intake and regular
exercise have been shown to reduce the serum concentrations of IL-6, TNFα and are associated
with reduced activity of tumor-promoting transcription factors, including activator protein (AP)-1,
STAT3 and NF-kB in various tissues [51–54]. An emerging area of research is the role of extracellular
vesicles as a mode of intercellular communication regulating inflammation, insulin sensitivity and lipid
metabolism. Extracellular vesicles are produced and excreted by cells where they diffuse to neighboring
or distant sites carrying proteins, lipids and nucleic acids (for example messenger (m)RNAs, transfer
(t)RNAs and microRNAs), serving as a novel mechanism for intercellular communication [55,56].
Obesity has been linked with higher quantity of circulating extracellular vesicles [57,58] leading to
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the simulation of monocyte differentiation into active macrophages and inducing proinflammatory
cytokine secretion, such as IL-1 and TNF-α [59].
As mentioned above, the effects of obesity on immune homeostasis are not confined to circulating
cytokines but extend to the composition and phenotype of immune cell populations in peripheral
blood and tumor tissues. Perhaps most relevant to antitumor immune responses, increased levels
of myeloid-derived suppressor cells (MDSCs) have been reported in the peripheral blood of obese
human subjects [60]. MDSCs may serve to counteract inflammation and increase glucose tolerance [61]
in obese individuals yet they have also been implicated in blunting antitumor immune responses
in cancer patients through multiple mechanisms, including inhibition of tumor-infiltrating T cell
proliferation and function, recruitment of regulatory T cells (Tregs) and inhibiting natural killer (NK)
cell function [62]. Obesity-related modulation of NK cells through pathologically elevated levels of
leptin and IL-6 has been demonstrated to reduce cytotoxicity against malignant cells [63]. Similarly,
the frequencies of invariant natural killer T (iNKT) cells and mucosal associated invariant T (MAIT)
cells are diminished in the setting of obesity and can be restored following weight loss [64–66]. In mice,
higher levels of circulating dendritic cells [67] and intratumoral MDSCs [68] have been reported
in tumor-bearing obese than lean animals, a phenomenon also associated with poorer responses to
immunotherapy [69]. In addition to myeloid cells, other immune cell populations (for example T helper
(Th)1, Th17 and Treg lymphocytes) are altered in fat tissue of obese individuals [70–72]. The functional
significance of changes in the abundance or differentiation of these immune cells in adipose tissue to
tumor development in obese individuals remains elusive. Collectively, these data reinforce the notion
that excess adipose tissue has systemic effects on the innate and adaptive immune systems which,
in aggregate, compromise effective antitumor immune responses. (Figure 2) Much work remains to be
done to understand how changes in immune cell composition and phenotype are linked to endocrine
and paracrine effects exerted by adipose tissue-derived cytokines.
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macrophages in close proximity to adipocytes. Cytokines and adipokines secreted into the circulation, 
in concert with increased levels of myeloid-derived suppressor cells (MDSCs), are likely to contribute 
to the immunosuppressive microenvironment in tumor tissues. Calorie restriction reduces 
inflammation in adipose tissue by reducing T lymphocytes activity and increasing anti-inflammatory 
(M2-polarized) macrophages near adipocytes. Calorie restriction also reduces secreted levels of 
cytokines and adipokine and decreases levels of MDSC rendering the tumor microenvironment less 
immunosuppressive. 
4. Treating the Host: Diet and Pharmaceutical Intervention 
The close epidemiologic relationship between increased BMI, inflammation and cancer raises 
the question how best to correct and disrupt pathogenic mechanisms supporting tumor growth and 
treatment resistance. An obvious point of intervention is nutrition—which has effects on adipose 
Figure 2. Calorie restriction contes s he ffects of chronic i fl ation in adipose tissue on tumor
development and immune r sponse . Adip sues contain activated immune cells including
T lymphocytes (cluster of differ ntiation (C ) , ) lls and proinfla matory (M1-polarized)
macrophages in close proximity to adipocytes. Cytokines and adipokines secreted into the circulation,
in concert with increased levels of myeloid-derived suppressor cells (MDSCs), are likely to contribute to
the immunosuppressive microenvironment in tumor tissues. Calorie restriction reduces inflammation
in adipose tissue by reducing T lymphocytes activity and increasing anti-inflammatory (M2-polarized)
macrophages near adipocytes. Calorie restriction also reduces secreted levels of cytokines and adipokine
and decreases levels of MDSC rendering the tumor microenvironment less immunosuppressive.
4. Treating the Host: Diet and Pharmaceutical Intervention
The close epidemiologic relationship between increased BMI, inflammation and cancer raises
the question how best to correct and disrupt pathogenic mechanisms supporting tumor growth and
treatment resistance. An obvious point of interventi is trition—whic has effects on adipose
tissue mass and the hormones and intermediaries produced by fat cells. In addition, numerous agents
currently used or tested for cancer treatment affect ‘metabolic’ targets. These include inhibition of
anabolic mechanisms, i.e., the insulin growth factor-1-receptor/protein kinase B (IGF1-R/PKB) axis and
mammalian target of rapamycin (mTOR) and activation of catabolic mediators including adenosine
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monophosphate-activated protein kinase (AMPK) [73]. The IGF-1R-signaling pathway is known to
play a role in the progression and metastasis of many types of cancers. The phosphorylation of the
receptor tyrosine kinase domain has been shown to trigger the downstream survival pathway involved
in malignant transformation. Increased expression of the components of the IGF-1R-signaling pathway
including IGF-1, IGF-1R have been associated with radio and chemoresistance. Adipocytes of obese
individuals produce a 2-fold increase in IGF-1 compared to normal lean individuals [74] (Figure 3).
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Conventional approaches to cancer treatment regimens employ traditional classification of malignant
tumors (TNM) into stages utilizing alphanumeric codes describing size of the primary tumor, nearby
(regional) lymph node involvement and distant metastases. Future treatment approaches should
aim to combine precision “tumor” medicine with precision “host” medicine to optimize clinical
outcomes. Precision medicine attempts to personalize treatment based on molecular profiles of the
tumor. This should e combined with n approach to account for distinct patient characteristics, such
as body mass, disease tates co ferring hronic inflammat on and immunologic dysfunction.
4.1. Diet Improves Sensitivity to Cancer Treatments
While t e benefits of dietary interventions on et li arameters, including improved blood
glucose, in ulin and triglyceride profiles, have been d scribed for decades, recent r sea ch has revealed
that di tary interventions also has direct effects on can er cell survival and growth by increasing
apoptosis and decreasing the rate of proliferation, angiogenesis, hormone levels and growth factors [75].
In fact, a systematic review of 59 studies on dietary restriction in murine cancer models reveals that the
therapeutic effect of CR is broad-based and applicable across multiple tumor entities and significantly
reduces the odds ratio (OR) of cancer induction (OR 0.2, 95% CI: 0.12–0.34 relative to controls) [76].
These encouraging results have motivated several clinical weight loss trials using hypocaloric diets
in oncology patient populations. Preclinical evidence strongly supports the notion that nutrient
restriction can be used concurrently with radiation to increase efficacy. In several models of triple
negative breast cancer (4T1 and 67NR), CR has been shown to have an additive effect to decrease
the primary tumor growth when combined with radiation and was noted to inhibit the IGF-1R/Akt
pathway [77]. A similar effect was noted in both hormone sensitive (LNCaP) and hormone insensitive
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(PC3) models of prostate cancer in which CR increased the efficacy of radiation [78]. In both the breast
and prostate cancer models, metastatic burden was decreased and overall survival was increased.
Multiple in vivo studies in lung, colorectal, melanoma, pancreatic and breast cancer models [77,79,80]
have shown that short-term or time-restricted diet protect the normal cells from toxicities due to
radiation and chemotherapy. Normal cells are thought to protect themselves against the extreme
changes in their microenvironment caused by starvation by adapting, temporarily shutting down
growth pathways, decreasing IGF-1, increasing AMPK and using alternative sources of energy such
as ketone bodies. Tumor cells are however unable to adapt to the sudden changes caused by diet,
are unable to use alternate energy sources in absence of glucose and hence become more sensitive
to the treatment [81]. Exposure to a calorically restricted diet has been shown to reduce systemic
glucose, modulate IGF-1-signaling pathways and induce the activation of AMPK [82–84]. Furthermore,
preclinical and human evidence has shown that CR is associated with reduced inflammatory-signaling
cascades [85,86]. A multicenter trial conducted in healthy non-obese adults showed reductions
in circulating inflammatory markers, including intercellular adhesion molecule (ICAM)-1, leptin,
C-reactive protein and TNF-α in patients randomized to a 25% reduction in calories compared an
ad lib diet [87]. CR has also been shown to enhance immunosurveillance by increasing the tumor
infiltrating CD8+ T cells while reducing the regulatory T cells [88]. Ketogenic diets have also been
shown to enhance radiotherapy in both lung cancer and glioblastoma multiforme models. Lung cancer
xenografts (NCI-H292 and A549) were shown to be more responsive to the combination of radiation
and chemotherapy in the presence of a ketogenic diet due to enhanced oxidative damage mediated by
lipid peroxidation which led to decreased proliferation [89]. A ketogenic diet also enhanced radiation
in a malignant glioma model (GL261), where animals receiving KetoCal had a better imaging response
and freedom from tumor-recurrence compared to standard diet animals [90]. Furthermore, dietary
interventions such as CR and the ketogenic diet may be utilized to induce radioprotective effects via a
“differential stress resistance” where healthy cells are better able to adapt to glucose starvation than
cancer cells [91].
In addition to the aforementioned macro alterations to diet, modifications of individual nutrients
have been shown to alter sensitivities to anticancer therapies as well. Fructose and non-essential
amino acids, such as serine, are implicated in cancer cell metabolism and their deprivation serves
as a promising adjunct to anticancer therapies [92,93]. Methionine restriction has been shown to
enhance therapeutic response in a variety of murine models, including sarcomas [94], gliomas [95],
prostate cancers [96], breast cancers [97–99] and melanomas [100]. Additional nutrient targets that
are active areas of research include asparagine [101], arginine [102,103], cystine [104], aspartate and
glutamine [105], among others [92]. Together, these findings suggest a therapeutic potential from
depriving patients of specific, individual nutrients as apart the effort to further precision medicine and
optimize clinical outcomes.
4.2. Clinical Trials Using Dietary Alterations with Radiation
These encouraging preclinical data have spawned several clinical trials using diet coupled with
radiation. (Table 1) Several trials have been accruing patients to ketogenic diet during radiation [106].
At the University of Iowa, ketogenic diet is being evaluated concurrently with radiation in three phase
I trials: one for locally advanced pancreatic cancer, one for lung cancer and the last for patients with
head and neck cancer. Tolerability of the diet is being assessed along with serum glucose, ketone
and oxidative stress markers. Investigators from Leopoldina Hospital Schweinfurt in Germany have
completed an initial analysis of six patients who underwent ketogenic diet with radiation and were
noted to be compliant and lost fat mass by the completion of their intervention [107]. Our group recently
finished recruiting patients that underwent a 25% reduction in calories during radiation for early
stage breast cancers in the caloric restriction for oncology research trial (CaReFOR) [NCT01819233].
This pilot trial measured dietary adherence, body metrics, quality of life metrics, in addition to serum
measures of inflammation including adipokines and IGF-1.
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Table 1. Preclinical studies evaluating the impact of obesity, dietary modification and pharmacologic modulation on the response to cancer-directed therapy.
First Author Cancer Type Experimental Design Results
Obesity
James, B.R. et al. [67] renal cell carcinoma ♀BALB/c with renal cell carcinoma on chow or HFD (DIO model) DIO mice with RCC tumors show ↑ in T cell suppressive dendriticcell. ↑ in tumor outgrowth.
James, B.R. et al. [69] renal cell carcinoma
♀BALB/c with renal cell carcinoma on chow or HFD (DIO model)
treated with TRAIL-encoding recombinant adenovirus
(Ad5-TRAIL) in combination with CpG-containing
oligodeoxynucleotides (Ad5-TRAIL/CpG) of RCC.
Ad5-TRAIL/CpG unable to reduce MDSC in tumors of DIO mice.
Treatment ↑ CD8 T cell in lean mice, but not DIO mice. Poor anti
tumor response.
Hale, M. et al. [68] renal cell carcinoma ♀BALB/c with renal cell carcinoma on chow or HFD (DIO model) DIO mice showed ↑ in accumulation of MDSC in tumors and spleens.
Dietary Intervention
Saleh, A.D. et al. [77] breast cancer
♀BALB/c mice with orthotopic 67NR or 4T1 TNBC tumors on ADF
or CR diet +/− 8 Gy dose of RT
RT caused 16% and ADF + RT 25% growth delay in 67NR tumors.
RT caused 23% and ADF + RT 45% growth delay in 4T1 tumors.
RT caused 23% and CR + RT 86% growth delay in 4T1 tumors.
ADF and CR improved RT response in TNBC tumors
Simone, B. et al. [78] prostate cancer ♂nude mice with LNCaP or PC3 tumors on CR diet +/− 8 Gy doseof RT
CR+ RT caused 80% and 55% tumor growth reduction in PC3 and
LNCaP tumors, respectively.
CR + RT increased time to metastases.
CR + RT increased apoptosis and decreased proliferation of tumor.
↑ radiosensitivity hormone responsive and hormone insensitive
prostate tumors.
Bianchi, G. et al. [79] colorectal cancer
♀BALB/c mice with subcutaneous colorectal tumors treated with
STS with/without oxaliplatin
Short term starvation (STS) augmented the response of oxaliplatin in
reducing tumor growth and glucose uptake consumption in
colorectal tumors
Allen, B.G. [89] lung cancer
♀athymic-nu/nu mice with subcutaneous A549 or H292 lung cancer
xenograft treated with chow or KetoCal diet +/− 12 Gy dose of IR
(fractionated) +/− carboplatin (15 mg/kg x3 doses)
KD + IR with/without carboplatin caused a significant tumor growth
reduction compared to chow diet combined with same treatments.
KD + IR group showed significantly increased survival compared to
IR alone.
KD + IR + carboplatin group also showed increased survival
compared to IR+ carboplatin alone.
KD + IR tumors showed ↑ 4-HNE modified proteins compared to IR
alone indicating oxidative stress caused by lipid peroxidation.
Abdelwahab, M.G. et al. [90] glioma albino C57BL/6 mice with GL261 glioma tumors on chow orKetoCal +/− 8 Gy fractionated dose of RT
KD + IR increased efficiency of RT compared to RT alone and KD ↑
median survival.
KD + IR mice showed exponential decline in tumor growth till D60.
On reintroduction of chow diet at D100, no recurrence of
glioblastoma observed.
Orlandella R.M. et al. [108] renal cell carcinoma BALB/c mice with renal carcinoma tumors treated with acarbose Mice with tumors on acarbose showed ↑ in splenic and intra-tumoralCD8 T cells compared to control.
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Table 1. Cont.
First Author Cancer Type Experimental Design Results
Pharmacological Modulation of Metabolism
Zhao, F. et al. [109] breast cancer human breast cancer cells MDA-MB-231 and MCF-7 treated withdifferent doses of RT 0.25, 0.50 and 0.75 Gy +/−WZB117
RT ↑mRNA and protein expression of Glut1, ↑ glucose uptake and
induces radioresistance in breast cancer cells. Inhibition of Glut1
with inhibitor WZB117 + RT ↑ sensitivity of resistant cells to RT.
Maggiorella, L. et al. [110] Head and Neck Cancer hep-2 cells treated with ritonavir (200 µM) or RT (5 Gy) or ritonavir
+ RT
Glut4 antagonist ritonavir enhanced sensitivity to RT in Hep2 cells
and ↑ Hep2 cell death
Cao, W. et al. [111] prostate cancer prostate cancer PC3-Bcl-2 cells and PC3-Neo cells treated with IC25concentration of dichloroacetate (DCA) and 2 Gy dose of RT
Prostate cancer cells pretreated with CRM DCA showed ↑ sensitivity
to RT in both cell lines. ↓ cell survival in PC3-Neo cells compared to
PC-3-Bcl-2 cells.
Rae, C. et al. [112] prostate cancer prostate cancer PC3 and LNCaP cells treated with C75 (35 µM) +/−2 Gy
Fatty acid synthase inhibitor C75 in combination with RT caused
maximum cell death and apoptosis compared to RT administered
before or after C75.
C75 + RT also showed ↑ in time to growth of LNCaP spheroids.
Beltran, P.J. et al. [113] pancreatic cancer
pancreatic BxPC-3 and MiaPaCa2 treated AMG479 +/−
gemcitabine♀athymic nude mice with BxPC3 or MiaPaCa2 tumors
+AMG479 +/− gemcitabine
IGF-1R inhibitor AMG479 in combination with gemcitabine ↓
viability of the pancreatic cell line in a dose dependent manner.
AMG479 + gemcitabine caused tumor growth reduction compared to
gemcitabine alone.
Abbreviations: HFD—high fat diet; DIO—diet induced obesity; MDSC—myeloid derived suppressor cells; TNBC—triple negative breast cancer; ADF—alternate day feeding; CR—calorie
restriction; RT/IR—radiation therapy; KD—ketogenic diet; 4—HNE—4—hydroxynonenal; IC—inhibitory concentration; +/−—with or without; ↑—increased; ↓—decreased/reduced.
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Clinicians should proceed with caution when selecting which patients may benefit from enrollment
in clinical trials evaluating the coupling of dietary interventions with radiation. Malnutrition
and subsequent loss of muscle mass occurs frequently following cancer therapies, particularly
in patients with advanced-stage disease or head and neck malignancies and is associated with poor
outcomes [114,115]. Profound nutritional deficits are also associated with decreased quality of life,
decreased functional status and poor treatment compliance [116–118]. Clinical trials that alter a
patient’s diet should involve the expertise of a dietician with regimented contact during and following
cancer-directed therapies [119,120]. The era of personalized medicine incorporating both host- and
tumor-specific factors represents an exciting strategy for furthering cancer treatments, but great care
should be taken to enroll patients likely to benefit from dietary interventions.
4.3. Clinical Trials Using Dietary Alterations to Prevent Radiation Toxicity
While it is thought that dietary interventions can increase efficacy of radiation on tumor cells, it is
also suspected that diet may play a protective role on normal tissues and prevent toxicity. Several
studies are assessing the use of dietary alterations to prevent gastrointestinal toxicity from pelvic
radiation with the Royal Marsden evaluating low- vs. high-fiber diet and the University College of
London Hospitals using probiotics [121].
5. Pharmacological Modulation of Metabolism
Though dietary measures hold promise for our changing patient population, pharmacologic
intervention combined with radiation could yield a similar benefit and may be better tolerated by the
general population.
To date, pharmacologic agents that harness the beneficial effects of metabolism, are just beginning
to be combined with radiation to try and increase efficacy of treatment. Metformin, a drug widely used
in the management of type 2 diabetes, is one such example. This drug was first noted to be beneficial in
reducing cancer mortality in epidemiological studies of both normal weight and obese patients [122,123].
Metformin affects AMP-K and mTOR-signaling and multiple preclinical studies have shown that
modulation of these pathways may affect radiation sensitivity of a variety of cancer types, including
prostate, breast, esophageal and lung cancers [124]. In addition, metformin targets tumor-associated
macrophages (TAM) by reducing TAM M1-like polarization thereby decreasing cytokine secretion of
IL-1β, TNFα and IL-10 and affecting cancer outcomes such as reducing metastases [125]. Currently,
multiple clinical trials evaluating the addition of metformin to radiation across a variety of malignant
primaries are ongoing.
Preclinical evaluation of other pharmacologic inhibitors of metabolism have also been performed
to determine which may be combined with radiation in the clinic. In the obese state, overexpression of
glucose transporters allows for an increase in available energy from the host to the tumor. In vitro
inhibition of the glucose transporters Glut 1 (WZB117) and Glut 4 (ritonavir) enhanced radiosensitivity
in both breast [109] and head and neck cancer [110] cells, respectively. ritonavir may also contribute to
radiosensitization via inhibition of Akt-signaling [126]. Acting in a similar manner, glycolysis inhibitors
and CR mimetics (CRM) have also been shown to affect energy and increase radiation sensitivity with
2-deoxy-D-glucose (2-DG) used in glioblastomas models [127] and dichloroacetic acid (PDK inhibitor)
in prostate cancer models [111]. Other CRMs have also been shown to improve chemotherapy and
immunotherapy response by depleting regulatory T cells and increasing infiltrating CD8+ T cells,
including hydroxycitrate in NSCLC [128] and acarbose in renal cell carcinoma [108]. Another strategy,
inhibiting fatty acid synthase with either cerulenin or orlistat has notably increased radiation sensitivity
in both prostate [112] and head and neck squamous cell cancers [129], respectively. Preclinical studies
using IGF-1R targeting antibodies, tyrosine kinase inhibitors and IGF-1/2 neutralizing antibodies to
target the IGF-1R pathway have shown benefits in solid and hematological tumors [130]. However, even
though the IGF-1R targeting antibodies AMG-479, IMC-A12 (cixutumumab) and TKI NVP-AEW541
have been shown to reduce tumor proliferation in pancreatic [113], breast cancer [131] and endometrial
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cancer [132,133] cells in preclinical models, they are likely ineffective as monotherapies. In summary,
preclinical models have shown promise when radiation is coupled with inhibitors of metabolism.
Clinical results with other ‘metabolic regulators’ in conjunction with radiation, however, have
largely been less encouraging. For example, inhibition of mTOR or PI3K, key metabolic pathways
known to be regulated by nutrients, concurrently with radiation has demonstrated no discernible
clinical benefit in rectal cancer [134,135], or high grade gliomas [136]. In addition to the less than
ideal clinical results, it seems toxicity such as pulmonary fibrosis and infection rates may be increased
with these combination therapies [136–138]. Further evaluation of alternative metabolic regulators
is encouraged, however. A clinical trial using 2DG, an inhibitor of glucose transport and glycolysis,
with radiation demonstrated improved local tumor control in glioblastomas [127]. Promising results
continue to set the stage for the design and implementation of further clinical trials assessing modulation
of the metabolic process as an adjunct to contemporary cancer treatment modalities.
6. Conclusions
Given the global epidemic of obesity, the metabolic state of the host as it relates to cancer incidence,
treatment outcomes and tumor biology, deserves heightened scrutiny. Combining the pleiotropic effects
of metabolically targeted interventions with contemporary cancer treatment modalities may improve
local tumor control, reduce normal tissue damage and lead to better outcomes for patients. Due to
the rapid development of immunotherapy, systemic effects of metabolic deregulation on antitumor
immune responses are likely to be a major focus of these efforts. It is envisioned that these studies will
not only reinforce the utility of current dietary approaches prior to and during cancer therapy, but also
reveal whether pharmacological modifiers of metabolism will be of further benefit. Incorporation of
both host- and tumor-specific factors represents an exciting strategy for furthering cancer treatments,
however, clinicians should proceed with caution when selecting which patients may derive benefit
from enrollment in clinical trials evaluating of dietary interventions as an adjunct to radiation. Future
work into the clinical translations and mechanisms by which dietary interventions improve tumor
response to radiotherapy is warranted.
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